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1. Introduction 
1.1 Early detection of disease 
Early detection of a disease is very important since it greatly improves the individual’s 
chance of responding well to treatment. For example, the 5-year survival rate from prostate 
cancer is nearly 100% if it is detected early [http://www.toacorn.com/news/2005/1027/ 
Health_and_Wellness/077.html]. Similarly, the 5-year survival rate for ovarian cancer is 
95% if caught early, but since 75% of the cases are first observed in the later stages of the 
disease, the overall 5-year survival rate is less than 50% [http://www.information-about-
ovarian-cancer.com/]. It would be nice if there was a single test to determine if an 
individual had cancer somewhere in their body, but unfortunately such a test does not exist. 
While all cancers have many factors in common, tissue differences and the body’s response 
to different cancers make the test for ovarian cancer (CA125) very different from the test for 
prostate cancer (PSA). The lack of sufficient sensitivity and specificity has recently resulted 
in the recommendation that PSA no longer be used as a potential marker of prostate cancer 
[http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm]. 
Even within the same tissue, all cancers are not necessarily the same. It is well known that 
there are two major types of lung cancer, small cell lung cancer (SCLG) and non-small cell 
lung cancer (NSCLC). It is also known that NSCLC has three major sub-types; adeno-
carcinoma (AC), squamous cell carcinoma (SCC), and large cell undifferentiated carcinoma 
(LCUC). Each of these has differences in the biochemical processes going on within the 
cancer cell and one should not expect that the detection, or necessarily the treatment, of 
these cancers will be the same. Of the four recognized forms of lung cancer (SCLG, AC, SCC 
and LCUC), the latter three are strictly differentiated by appearances of the cell under the 
microscope. It is possible that the underlying biochemical processes of an AC cell in one 
individual are significantly different than the biochemical processes in another individual 
with a cancer that appears similar. Therefore, each of these categories of lung cancer may be 
composed of one or more states. While the disease category represents the name of the 
disease based on some experimental observation, the disease state represents a grouping 
based on the underlying biochemical processes within the diseased cell. The detection of a 
disease and its treatment should be relative to specific disease states, not a disease category 
or individuals within that category. 
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1.2 Types of classifiers 
A high-quality classifier would be a great aide in the early detection of disease. The general 
procedure is to obtain a biological specimen and search for one or more features that 
correctly classify the individual. The specimen can be blood, urine, mucous, or tissue 
sample, for example, and the feature can be the expression level of mRNA, a protein, or a 
metabolite. The construction of the classifier starts with obtaining a large number of features 
from individuals with known phenotypes, known as the training set, and constructing a 
classifier that sufficiently predicts each sample’s phenotype. This classifier is then used on a 
second set of samples of known phenotype, called the testing set, to determine its overall 
accuracy. Since the number of features will be much larger than the number of samples in 
the training set, the construction of a classifier suffers from the “curse of dimensionality” 
[Bellman, 1957, 1961, 2003]. If the training set contains Nh healthy samples and Nd diseased 
samples, then virtually any classifier that uses the smaller of Nh and Nd features, such as 
their social security numbers, can correctly classify all samples in the training set. This 
extreme example would represent a case where the classifier is fitting the individuals in the 
training set and not their phenotype. The goal is to choose a relatively small number of 
features that correctly distinguishes the samples. 
Two extremes in the total range of possible classifiers are fingerprint-based and biomarker-
based classifiers. A fingerprint-based classifier uses a collection of features, which is also 
known as a panel of markers. If two individuals have the same pattern in this set of features 
(i.e. similar fingerprints), and one is known to have a particular disease, it is assumed that 
the other has this same disease. A biomarker-based classifier tries to find a very small 
number of features that distinguishes all healthy samples from all diseased samples. In other 
words, a biomarker-based classifier tries to cluster all samples of the same phenotype into 
the smallest possible number of clusters. The optimum biomarker would distinguish all 
healthy from all diseased samples, resulting in a single healthy cluster and a single disease 
cluster. 
1.3 Selecting features 
A major difference between fingerprint-based and biomarker-based classifiers is how the 
features are selected. In a fingerprint-based classifier, the actual classifier is used to 
determine who well a given set of features distinguishes the samples. An overriding 
heuristic is used to determine what set of features is tested in the classifier, and the quality 
of the classification can be used to determine which feature set is tried next. This is known 
as a wrapper method. In contrast, a biomarker-based classifier uses one or more procedures to 
determine which features successfully distinguish some or all of the samples in the training 
set. This set of putative biomarkers is then used in a different classifier, either individually 
or a small number together, to determine how well the healthy samples can be 
distinguished from the diseased samples. In other words, the selection of features for a 
biomarker-based classifier uses a filter method. 
Many different procedures can be used in the wrapper method to find the optimal set of 
markers. Three major classes of procedures are forward-selection, reverse-selection, and 
multidimensional searches. The simplest forward-selection method is a Greedy Search. In 
this procedure all features are individually tested in the classifier and the one that performs 
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the best is retained. All remaining features are then tested in combination with this best 
feature to find the feature-pair that performs the best. This procedure continues until either 
the addition of an additional feature does not improve the classification or a pre-set number 
of features are selected. An extension of this Greedy Search is known as Branch-and-Bound. 
In this latter procedure multiple classifiers are retained at each cycle and the search results 
in a population of classifiers that have the highest accuracy. 
Reverse-selection works in the opposite direction. Initially, all features are used in the 
classifier and features that are not important to the classification are removed. In cases 
where the number of features is larger than the number of samples, special procedures need 
to be used to ensure that an important feature is not removed in the early steps of the 
reduction. 
Multidimensional searches use a pre-defined number of features and try different 
combinations of features in the classifier. Examples of multidimensional search techniques 
are Simulated Annealing, Tabu Search, Gibbs Sampling, Genetic Algorithm, Evolutionary 
Programming, Ant Colony Optimization, and Particle Swarm Optimization. The first three 
techniques modify a single set of features while the latter four use a population of sets, 
where each feature set is changed throughout the search to find one or more optimal sets. It 
should be noted that in a Genetic Algorithm the number of features in the set can be 
reduced, so the pre-defined number should be considered a maximum number of allowed 
features in the final set. 
The goal of each wrapper search technique is to find the optimal set of features, and 
therefore are approximations to an exhaustive search. If the objective is to find the best set of 
k features from a total set of K features, the number of unique combinations is generally 
given by ቀ݇ܭቁ. If there are a total of 300 features and the goal is to find the best set of seven 
features, an exhaustive search would require examining 4.04x1013 unique sets of features. 
The situation is slightly more complicated for a decision tree. In this case the order of the 
features is important since this order determines if the feature acts on the entire set of 
samples, or a particular subset of samples. Here, the number of possible combinations is ௄!ሺ௄ି௞ሻ! and an exhaustive search of 300 features to find the best seven-node decision tree 
would require examining 2.04x1017 trees. Since this is not computationally feasible, any 
result from a fingerprint-based classifier should be considered as a lower-bound to the 
accuracy of the classification algorithm. 
In contrast, the search for the search for the best biomarker-based classifier is exhaustive. All 
features are examined by each filtering method and all combinations of putative biomarkers 
can be used in the final classifier. 
1.4 Fingerprint-based classifiers 
Informatic analysis has led to a new paradigm for classification known as fingerprinting or 
pattern matching. In this paradigm, individuals are classified based upon a particular 
pattern of intensities [Petricoin et al., 2003]. If an untested individual has the same pattern as 
a known individual, then these two have the same classification. The simplest fingerprint-
based classifier is a decision tree (Figure 1). In all known applications of a decision tree to 
produce a classifier using spectral data [Ho et al., 2006; Liu et al., 2005; Yang et al., 2005; Yu 
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et al., 2005], a single scoring metric (e.g. Gini Index, entropy gain, etc.) was used to 
determine the cut point at a given node so that the two daughter nodes were as 
homogeneous as possible for one or more categories (e.g. diseased versus healthy). Given 
the general structure of a decision tree in Figure 1, the root node (Node 1) would contain all 
training samples and an m/z value, or feature, and its cut point would be selected that best 
separates diseased and healthy individuals between Nodes 2 and 3. If there was still enough 
of a mixture in Node 2, for example, a second feature would be chosen based on the same 
metric that would separate the individuals into Nodes 4 and 5. The same process would be 
used for all heterogeneous nodes until there was a sufficient domination of one category 
over another. 
 
Fig. 1. Example of a 7-node decision tree. 
Decision Support also uses decision trees, but an independent question is asked at each level 
in the tree. For example, Node 1 may be used to separate the individuals by gender, race, or 
other genetic difference, and then different features may be used to separate samples 
obtained from affected and healthy patients at a given level of stratification. Since the 
stratifying variables are not known ahead of time, there is no way to know the proper metric 
that should initially separate the training set. Therefore, the procedure used here is to 
construct unconstrained decision trees that best classify the training individuals. 
The medoid classification algorithm is a best attempt at reproducing the algorithm used in 
many of the studies conducted in the laboratories of Emmanuel Petricoin and Lance Liotta 
[Browers et al., 2005; Conrads et al., 2004; Ornstein et al., 2004; Petricoin et al., 2004; 
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Srinivasan et al., 2006; Stone et al., 2005]. While these authors stated that their algorithm was 
quite similar to a Self-Organizing Map (SOM), their algorithm, as they described it, has 
virtually nothing in common with a SOM. In a SOM [Kohonen, 1988], the layout of the cells 
is determined a priori, as are the number of features, n, used in the separation. In general, the 
cells are placed in a rectangular or hexagonal pattern, with a maximum of four or six 
adjacent cells, respectively. The cells are seeded with random centroids that represent the n-
dimensional coordinates of each cell. The first training sample is assigned to the cell with the 
closest centroid and the centroids of this and all the other cells are significantly shifted 
towards this sample. This procedure is repeated for all samples. Once all samples have been 
processed, the algorithm repetitively cycles through the list of training samples. In each 
subsequent cycle, the extent to which the centroid of the cell it is assigned to shifts towards 
that sample decreases, as does the extent to which the other centroids are affected. This shift 
becomes significantly smaller for cells that are further from the selected cell, as defined by 
the initial mapping. When finished, all samples are assigned to cells and each centroid 
represents an approximate average of the n features for all samples in that cell, and the 
distance between centroids increases as the cells become further apart in the pre-defined 
map. 
In contrast, the algorithm used in the references cited above places the first training sample 
as the center of the first cell, and this cell is classified as the category of this sample. Since it 
is sample-centered, each cell has a medoid not a centroid. Each cell is given a constant trust 
radius, r. If the second sample has a distance that is larger than r from the first, it is assigned 
to a second cell and that cell is classified by its category; otherwise it is assigned to the first 
cell. This process continues until all training samples have been analyzed. 
Therefore, a SOM has a fixed number of cells, each cell is described by a centroid, and the 
algorithm cycles through the training data many times to adjust the centroid’s coordinates. 
The algorithm used by the groups of Petricoin and Liotta has an undefined number of cells, 
each described by a single sample, and the training data is only processed once. 
Also grouped within the class of fingerprint-based classifiers are Support Vector Machines 
and Linear Discriminant Analysis. A Support Vector Machine (SVM) [Boser et al., 1992; 
Vapnik, 1998] is a kernel-based learning system. SVM searches for the optimal hyperplane 
that maximizes the margin of separation between the hyperplane and the closest data points 
on both sides of the hyperplane. Linear Discriminant Analysis (LDA) [Fukunaga, 1990] is a 
supervised learning algorithm. LDA finds the linear combination of features that maximize 
the between-class scatter and simultaneously minimize the within-class scatter to achieve 
maximum discrimination in a dataset. The within-class scatter matrix may become singular 
if the sample size is smaller than the dimensionality of the search space (number of 
features), but several techniques are available to handle this situation. 
1.5 Biomarker-based classifiers 
An example if a state-specific marker is shown in Figure 2. Each “+” represents, for example, 
the blood concentration of a particular biochemical. The individuals in the left column are in 
a specific disease state, while those in the right column are not and are therefore considered 
to be in a healthy state, at least with respect to this disease. Individuals in each state have 
different blood concentrations of this biochemical due to genetic and environmental 
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differences between individuals and any experimental uncertainty in the measurement. 
What is clear is that the range of concentrations for individuals in the disease state is 
significantly higher than for those not in this state. Such a marker can be used to classify the 
individuals into three groups; they are in the disease state if the blood concentration is 
above an upper threshold, they are not in this disease state if the concentration is below a 
lower threshold, and they are undetermined if the blood concentration is between these 
thresholds. 
 
Fig. 2. Values of a state-specific marker for individuals in a disease state (left) and in a 
healthy state (right). 
While blood concentrations of biochemicals are one possible means of examination, it is not 
the only one. Concentrations of biochemicals in the urine are another, but this can be 
extended to tears, mucous, or virtually any biofluid. Instead of directly measuring the 
concentration of specific compounds, mass spectra (with or without pre-fractionation) and 
2D NMR of these biofluids can also be used to measure abundance. The difference with 
these spectral methods is that the abundance of a compound can be examined from one 
individual to the next without knowing the identity of this compound. Therefore, examining 
the intensity or area of spectral peaks is called an undirected search since a list of 
compounds to examine was not created before hand, while direct measurements of 
concentrations or intensity measurements from microarray experiments are directed 
searches since the search is over a set of pre-defined compounds. 
In general, the set of biochemicals whose concentration is directly measured or examined by 
microarray analysis, as well as the set of peaks present in various spectra, are known as 
features. For each individual, each of these features has a corresponding value. This value 
can be the concentration, the logarithm of the relative fluorescence intensity, or the intensity 
or area of the spectral peak. The search for a putative biomarker is over the set of N available 
features, and each individual is represented by an array of N numbers representing the 
values of these features. 
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Since the values of many features are known for each individual, it is possible to construct 
classifiers using two or more features. An algorithm would search through sets of two or more 
features to find a set that optimally classified a given set of individuals, which is known as a 
training set. The goal is to maximize the number of correctly classified individuals, so if two 
features are used and one is that shown in Figure 2, the second feature would try to correctly 
resolve those in the undetermined region without upsetting the correct classification of the 
other individuals. Therefore, the action of this second feature in the classifier is to specifically 
act on those individuals in the undetermined region. The first feature (Figure 2) therefore is a 
state-specific marker since its intensity is largely controlled by the state of the individual, while 
the second feature is individual-specific since it only acts on those individuals who have an 
intensity of the first feature in the undetermined region. 
 
                               
Fig. 3. (a) Scatter plot for diseased (red) and healthy (green) individuals using the values of a 
pair of correlated markers; (b) Values for these markers assuming one state for each category; 
and (c) Values for these markers assuming two disease states and one healthy state. 
(a) 
(b) (c) 
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This argument suggests that statistical methods which find features that are significantly 
different in magnitude depending upon an individual’s state is all that is needed to find any 
state-specific markers. These independent markers can be found if both the healthy and 
diseased categories are represented by a single state. Figure 3 displays a situation where the 
diseased category (shown in red) is actually composed of two states (D1 and D2). This can 
only be seen through the action of a concerted pair of markers, Marker 1 and Marker 2. State 
D1 has a high intensity in Marker 1 while State D2 has a high intensity in Marker 2, while 
the healthy individuals have a low intensity in both features. Figure 3 shows intensity plots 
for these two markers under the assumption that there is a single diseased state and a single 
healthy state. It is questionable whether a given statistical method would find the difference 
in the intensities of these features significant. Only by correctly distinguishing the state if 
each individual can one see that Marker 1 is a good classifier for State D1 and Marker 2 for 
State D2 (Figure 3). 
1.6 Bias, chance and generalizability 
Ransohoff [2005a, 2005b] has presented three factors that must be explored in any 
classification study; bias, chance and generalizability. Until now, any marker that clearly 
distinguishes individuals in different states, either alone or in a concerted action with 
another feature, is denoted as a putative biomarker. Before it can become a true biomarker 
one has to ensure that the marker is not due to an underlying bias. For example, if all 
individuals in the disease state are being given a particular drug, there is no way to 
determine if the change in the feature value is due to the disease or the drug. There is no 
way to remove this bias, and such situations should be excluded in the initial study design. 
As a second example, the individuals in the disease state may be significantly older than 
those in the healthy state. Many diseases are more prevalent in older individuals and it may 
be very difficult to find age-matched patients who are disease free or are not on a regular 
drug treatment. If a random collection of age-matched individuals without signs of the 
particular disease state are taken to be the healthy category, it is likely that this category will 
be composed of a number of states due to other diseases or drug responses. Markers 
separating each of these “healthy” states from the disease state would have to be found. 
Finding all required biomarkers would be very difficult within a single set of features. In 
addition, if the number of individuals in a particular healthy state was small, the 
significance of any biomarker may be suspect (see below). For this case, the affect of age can 
be examined. If there is no correlation between the feature value and the age of the 
individual in either the disease or healthy state, one can conclude that age is not the source 
of the difference in feature values. 
If the available individuals in the disease and healthy states are divided into a training set 
and a testing set, it is theoretically possible to construct one or more classifiers using the 
training set that can accurately classify the individuals in the testing set without using a 
state-based marker. Such a classifier is a chance fit to the available data, and we have shown 
that accurate results can be obtained for certain classifiers without any state-specific marker 
being present in the set of available features. Therefore, simply constructing a good classifier 
is not sufficient to demonstrate the presence of a state-specific marker. 
The basic assumption is that if a classifier is able to accurately classify both a training set and 
a testing set of data, then this classifier will be useful for all individuals in the population 
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from which these individuals were taken. In other words, any classifier that accurately 
classifies a sufficient sample from a population should be generalizable to the entire 
population. We assert that this assumption may be true only if the classifier is strictly 
composed of state-specific markers. Any classifier that is a chance fit to the available data 
will not be generalizable to the entire population. 
1.7 Coverage, uniqueness, and significance 
The simplest example of fingerprinting is a straightforward decision tree, like the one shown 
in Figure 4. Assuming that the entire dataset is composed of 60 diseased and 60 healthy 
individuals, the intensity of Feature 1 splits the dataset into two groups; 40 diseased and 20 
healthy individuals if the intensity of this feature is below Cut-1 and 20 diseased and 40 
healthy individuals if its intensity is above Cut-1. The left branch is further divided using 
Feature 2 into a diseased node (D1) that contains 38 diseased and 3 healthy individuals and 
a healthy node (H1) that contains 2 diseased and 17 healthy individuals. The right branch is 
divided using Feature 3 into a healthy (H2) and a diseased (D2) terminal node. 
 
Fig. 4. (a) Hypothetical decision tree using all available data and (b) the corresponding tree 
when one-third of the samples are removed as testing data. 
Overall this decision tree would yield a sensitivity and a specificity of 90%, but the general 
procedure is to divide the data into a training set and a testing set and construct the 
classifier using only the training data. If one-third of the data was removed to form the 
testing data, the situation in Figure 4b could be produced. In this example, 16 of the 20 
healthy samples happened to come from H1 and 16 of 20 diseased samples from D1. This 
training distribution would make the use of Feature 2 unnecessary and may result in 
different features being used at each node. If only Features 1 and 3 were used, the training 
set would have a sensitivity of 90% and a specificity of 82.5%, while the testing data would 
have a sensitivity of 100% but a specificity of only 20%. The basic reason for this large 
change in sensitivity is that the fingerprint needed to describe the healthy subjects in Group 
H1 is no longer present in the training data. 
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Therefore, the first requirement of a fingerprinting method is that there must be a complete 
coverage of all required fingerprints in the training data. If a required fingerprint or 
proteomic pattern is missing from the training data (Figure 4), the quality of predictions for 
the testing data will either be greatly reduced or there will be a significant number of testing 
individuals that will receive an “undetermined” classification. 
If a fingerprinting classifier is found that performs extremely well on classifying the training 
data, but classifies the testing data poorly, one can either state that the classifier is 
insufficient and therefore not biologically relevant, or that there was an incorrect separation 
of training and validation data so that effective coverage of all important fingerprints was 
not present in the training data. Since the discriminating fingerprints are not known, proper 
coverage cannot be known, and therefore proper selection of the training data cannot be 
known. In addition, since the quality of classifying the testing set is the metric used to 
determine biological relevance, the testing set is used in the process of constructing the 
classifier and is therefore part of the training process. 
With these points in mind, an effective way to construct classifiers based on fingerprints is 
to include all data in the search for fingerprinting classifiers and then to selectively remove 
samples for the testing set in a way that preserves the coverage of the fingerprint in the 
training data. This statement does not suggest, in any way, that this procedure is used by 
other research groups who present fingerprinting classifiers, it simply states that this 
method is an effective way to ensure complete coverage in the training data and to 
effectively test for uniqueness. If Figure 4 was used as the basic classifier, all other possible 
three-node decision trees would have to be constructed and compared to a sensitivity and 
specificity of 90%. If no other three-node decision tree is found to have this overall accuracy, 
then the uniqueness of this classifier is established. Otherwise, each decision tree would 
have to be presented as a possible solution; since the important fingerprints are not known, 
the selection of the training set cannot be determined, and two different decision trees that 
imply different separations of training and validation data are therefore equally valid. 
Finally, the significance of a fingerprinting classifier needs to be established. Permutation 
testing is often used to test significance, but can be used in three different ways. In the 
Random Forest algorithm [Breiman, 2001] the intensities of a given feature are scrambled 
among all data in each testing set (i.e. the out-of-bag samples) to determine the importance 
of that feature. The phenotypes of the samples can also be scrambled a large number of 
times to determine the probability that the accuracy of a given classifier occurred by chance. 
In this application, the phenotypes will be scrambled amongst all data to determine if a new 
classifier of the same form (e.g. a three-node decision tree) can be constructed with 
comparable accuracy. The probability that random phenotypes can be classified to a given 
accuracy determines the significance of a given model. 
1.8 Proposed study 
To test the classification ability of different algorithms, this study will attempt to build 
classifiers from sets of 300 possible features. In each case, the intensities of the features will 
be determined using a random number generator. In other words, each classifier will 
attempt to distinguish healthy samples from diseased ones using data that contains no 
information. Results using DT and MCA classifiers have been previously presented [Luke & 
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Collins, 2008], but these will be included here to compare to SVM, LDA, and biomarker-
based classifiers. Exhaustive searches using DT, MCA, SVM and LDA are not 
computationally feasible, so the results presented here represent a lower bound to the 
accuracy that can be obtained from these methods with data that contains no information. It 
should also be stressed that 300 features is a very small number by current methods of 
analysis of biological samples, and the accuracy of all methods will not decrease as the 
number of features increases. 
2. Methods 
2.1 Decision tree 
For the symmetric, 7-node decision tree shown in Figure 1, a modified Evolutionary 
Programming (mEP) procedure is used. Each putative decision tree classifier is represented 
by two 7-element arrays; the first contains the feature used at each node and the second 
contains the cut values. Both arrays assumed the node ordering listed in Figure 1. The only 
caveats are that all seven features must be different and that this ordered septet of features 
cannot be the same as any other putative solution in either the parent or offspring 
populations. When a new putative decision tree is formed, a local search is used to find 
optimum cut points for this septet of features. 
The mEP procedure starts by randomly generating 2000 unique decision trees. Each decision 
tree has one or two of the features removed and unique features are selected, again 
requiring that the final septet is unique. The local search first tries to find optimum cut 
points for the new features that were added and then the search is over all seven cut points. 
The best set of cut points is combined with the septet of features to represent an offspring 
classifier. The score is the sum of the sensitivity and specificity for the training individuals 
over the eight terminal nodes. When the entire set of initial, or parent, decision trees have 
generated unique offspring, all 4000 scores are compared and the 2000 decision trees with 
the best score become parents for the next generation. This process is repeated for a total of 
4000 generations and the best classifiers in the final population are examined. 
2.2 Mediod classification algorithm 
While the algorithm described by Petricoin and Liotta [Browers et al., 2005; Conrads et al., 
2004; Ornstein et al., 2004; Petricoin et al., 2004; Srinivasan et al., 2006; Stone et al., 2005] 
used a genetic algorithm driver to search for an optimum set of features, allowing for 
different putative solutions to use different numbers of features (5-20 features), our 
algorithm uses a mEP feature selection algorithm and all putative solutions have the same 
number of features n. For a given value of n, n features were selected and the intensities of 
these features were rescaled for each individual using the following formula [Browers et al., 
2005; Conrads et al., 2004; Ornstein et al., 2004; Petricoin et al., 2004; Srinivasan et al., 2006; 
Stone et al., 2005]: 
 I’ = (I – Imin) / (Imax – Imin) (1) 
In this equation, I is a feature’s original intensity, I’ is it’s scaled intensity, and Imin and 
Imax are the minimum and maximum intensities found for the individual among the n 
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selected features, respectively. If Imin and Imax were from the same features in all samples, 
a baseline intensity would be subtracted and the remaining values scaled so that the largest 
intensity was 1.0. Each individual would then be represented as a point in an (n-2)-
dimensional unit cube. As designed, and as found in practice, Imin and Imax do not 
represent the same features from one individual to the next, so this interpretation does not 
hold. Therefore, each individual represents a point in an n-dimensional unit cube. 
As stated in the Background, the first training sample becomes the medoid of the first cell, 
with this cell being classified as the category of this sample. Each cell has a constant trust 
radius r, which is set to 0.1 (n)1/2, or ten percent of the maximum theoretical separation in 
this unit hypercube. If the second sample is within r of the first, it is placed in the first cell; 
otherwise it becomes the medoid of the second cell and that cell is characterized by the 
second sample’s category. This iteration continues until all training samples are processed. 
Each cell is then examined and the categories of all samples in the cell are compared to the 
cell’s classification. This calculation allows a sensitivity and specificity to be determined for 
the training data, and their sum represents the score for this set of n features. 
The mEP algorithm initially selects 2000 sets of n randomly selected features. The only 
caveat is that each set of n features must be different from all previously selected sets. The 
medoid classification algorithm then determines the score for each set of features. Again, 
each parent set of features generates an offspring set of features by randomly removing one 
or two of the features and replacing them with randomly selected features, requiring that 
this set be different from all feature sets in the parent population and in all offspring 
generated so far. The score of this feature set is determined and the score and feature set is 
stored in the offspring population. After all 2000 offspring have been generated the parent 
and offspring populations are combined. The 2000 feature sets with the best score are 
retained and become the parents for the next generation. 
It should be noted that for a set of n features, the number of unique cells that can be 
generated is on the order of 10n. Since no training set is ever this large (n is 5 or more), only a 
small fraction of the possible cells will be populated and classified. As will be shown in the 
next section, this limitation causes a significant number of the testing samples to be placed 
in an unclassified cell, though none of the publications that used this method [Browers et al., 
2005; Conrads et al., 2004; Ornstein et al., 2004; Petricoin et al., 2004; Srinivasan et al., 2006; 
Stone et al., 2005] reported an undetermined classification for any of the testing samples. 
Instead of searching through a large number of solutions that classified the training samples 
to a significant extent and find those that minimized the number of unclassified testing 
samples, we decided to use all samples and limit the number of cells. All samples were 
placed in the training set and the algorithm was run with the added requirement that any 
set of n features that produced more than a selected number of cells was given a score of 
zero. If the number of healthy and disease medoids are sufficiently small, all other samples 
could then be divided to place the required number in the testing set and the remainder 
would be part of the training. 
2.3 Support Vector Machine 
A support Vector Machine (SVM) [Boser et al., 1992; Vapnik, 1998] is a kernel-based learning 
system. SVM searches for the optimal hyperplane that maximizes the margin of separation 
between the hyperplane and the closest data points on both sides of the hyperplane. 
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Many features in a genomic or proteomic data are irrelevant or redundant that may likely 
hinder the performance of a classifier. It is essential to select informative features to build a 
classifier. A new selection criterion is presented with a performance found to be better than 
or comparable to the other criteria and is applied to LDA and linear SVM as a classification 
method. 
Support Vector Machines (SVM) [Boser, 1992; Vapnik, 1998], are becoming increasingly 
popular in biological problems [Noble, 2004]. SVM finds the optimal hyperplane that 
maximizes the margin of separation between the hyperplane and the closest data points on 
both sides of the hyperplane. Instead of error-risk minimization, the parameters of SVMs are 
determined on the basis of structural risk minimization. Thus, they have the tendency to 
overcome the overfitting problem. SVMs have been successful with a recursive procedure in 
selecting important features for cancer prediction [Guyon et al., 2002; Tang et al., 2007]. 
The decision functions (used to determine the class of a sample) of SVM and LDA can be 
expressed as a linear combination of features. They differ with regard to how the weights 
are determined. The weights (coefficients in the decision function) of features, which reflect 
the significance of the features for classification, can be served as a feature ranking criterion. 
This criterion corresponds to removing a feature whose elimination changes the objective 
function least [LeCun et al., 1990]. The criterion has been used with a recursive feature 
elimination scheme [Guyon et al., 2002], as described before. 
Instead of judging a feature by its contribution to the classification on the full dataset, this 
study uses a leave-one-out cross-validation to evaluate a feature’s contribution to the 
ensemble of classifiers. In other words, a classifier is re-trained on a new dataset formed by 
removing a sample from original dataset to obtain a weight for every feature. If a feature is 
important in differentiating samples, it should remain so when any sample is removed from 
a dataset. This can be indicated by the coefficient of variation of the weight value for each 
feature. The coefficient of variation is defined as the ratio of the standard deviation to the 
mean. A small coefficient of variation indicates smaller variation and a more consistent 
contribution of a feature to the sample classification. There are two ways to incorporate this 
criterion into the recursive selection process. One is to pre-select the number of iterations 
and the number of features at each iteration. This can be implemented by determining the 
coefficient of variation for each feature in current feature set and selecting k features with 
smallest coefficient of variation, where k is the predefined number of features for this 
iteration. In the second implementation, the number of iterations and the number of features 
at each iteration are determined during the selection process. It starts with all the features 
and can be described as follow: 
Step 1. Compute the coefficient of variation for each feature in current feature set. In every 
selection cycle, the procedure initially eliminates at least certain number of features. 
In this study, 10% of the current features, or 1 whichever is larger, with largest 
coefficient of variation are eliminated. 
Step 2. Let cmin denote the minimum coefficient of variation and cmax denote the maximum 
coefficient of variation among the remaining features. 
Step 3. Select k coefficient of variation, c1, c2,…, ck, such that cmin < c1 < c2 < …< ck = cmax and 
c1, c2,…,ck divided the interval [cmin, cmax] into k subintervals of equal lengths except 
possibly the interval [ck-1, cmax]. In this study, we choose k=8. 
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Step 4. Estimate, for each ci, i=1,2,…,k, the performance of a classifier, which uses all the 
features whose coefficient of variation is less than or equal to ci, from a cross-
validation, such as, leave-one-out cross-validation. 
Step 5. Find the smallest ci from c1, c2,…,ck which gives the best performance in Step 3. 
Step 6. Choose all the features from current feature set whose coefficient of variation are 
less than or equal to ci as the feature subset for this selection cycle. 
The selection process is repeated until only one feature remains. 
2.4 Linear Discriminate Analysis 
Linear Discriminant Analysis (LDA) [Fukunaga, 1990] is a supervised learning algorithm 
that finds the linear combination of features that maximize the between-class scatter and 
simultaneously minimize the within-class scatter to achieve maximum discrimination in a 
dataset. The within-class scatter matrix may become singular if the sample size is smaller 
than the dimensionality of the search space (number of features). To overcome the 
singularity problem, the pseudo-inverse [Golub & Van Loan, 1983] of the within-class 
scatter matrix is computed in this study. 
The computation of a pseudo-inverse in LDA may be demanding if the dimension of within-
class scatter matrix is too large. In this study diagonal LDA is used, which is the same as 
LDA except that the covariance matrices are assumed to be diagonal. The diagonal LDA has 
been reported to be performed remarkably well compared to more sophisticated methods 
[Dudoit et al., 2002]. A leave-one-out procedure is again used to determine the coefficient of 
variation for all remaining features, and procedure outlined above is used to reduce the 
feature set.  
2.5 Biomarker Discovery Kit 
The BioMarker Discovery Kit (BMDK) represents a suite of programs with the eventual goal 
of constructing one or more biomarker-based classifiers. Each biomarker represents a 
particular feature that is associated with a particular disease state represented by a subset of 
the available individuals. BMDK uses 10 different methods of analysis to identify putative 
biomarkers. These methods determine how well each feature distinguishes some or all of 
the individuals in a given histology. Descriptions of each filtering method are given 
elsewhere [http://isp.ncifcrf.gov/abcc/abcc-groups/simulation-and-modeling/biomarker-
discovery-kit/].The union of all features that have one of the top five scores for each of the 
10 methods produces the set of putative biomarkers. 
A single biocompound may produce more than one putative biomarker if the features are 
obtained from a mass spectroscopic investigation. For example, separate peaks for the +1 
and +2 ion or the biocompound alone and complexed with another compound are possible. 
Therefore, the Pearson’s correlation coefficient between all pairs of putative biomarkers 
across all samples is used to combine the putative biomarkers into groups. All other features 
in the dataset are then compared to the putative biomarkers within each group and are 
selected for examination if the correlation coefficient is 0.70 or higher.  Each group is then 
represented by the single feature with the largest maximum value; all other features are 
discarded. 
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The final classifier is based on a distance-dependent K-nearest neighbor (DD-KNN) 
algorithm. In this classifier the un-normalized probability that an unknown sample belongs 
to the same group as a neighbor is given by the inverse of their distance. To account for the 
situation where an unknown sample has no nearest neighbors, the classifier also contains a 
probability that its group is unknown. This probability linearly increases from 0.0 to 0.01 as 
the probability of being in a neighbors group decreases from 1.0 to 0.8. For smaller 
probabilities of belonging to the neighbor’s group, the probability of being unknown stays 
constant at 0.1. These probabilities are summed over all neighbors and scaled to a total 
probability of 1.0. Therefore, each unknown sample is described by a probability of 
belonging to Group-1 (e.g. healthy), Group-2 (e.g. diseased), and Undetermined. The final 
classification is given by a probability of membership of at least 0.5, or Undetermined if the 
probabilities of belonging to either group is less than 0.5. 
All of the putative biomarkers are individually used to find the best 1-feature DD-KNN 
algorithm, and this is followed by an exhaustive search over all sets of two and three 
putative biomarkers. In practice, six nearest neighbors are generally used but this number 
can be increased if there are a large number of samples; the number of neighbors should not 
decrease below six. The quality of the classifier is determined using a leave-one-out 
procedure since this method preserves the coverage (range of intensities) for the samples to 
the greatest extent. Each time an optimum classifier is found, the distribution of samples in 
feature-space is plotted to determine the number of disease state present for each category. 
3. Results 
Since the datasets examined in this investigation are produced using a random number 
generator, the goal is to simply determine a lower-bound to the accuracy that can be 
obtained for 300 features for different numbers of Cases and Controls. Since these labels 
really have no meaning, the accuracy of a classifier will be given by the sum of the 
sensitivity and specificity. These are lower bounds since only five different datasets are 
examined for each Case/Control combination, and for all methods but BMDK only a small 
fraction of all possible feature-combinations are explored. 
3.1 DT and MCA classifiers 
For the DT and MCA classifiers, it is assumed that the dataset is divided such that two-thirds 
of the samples in each group are used in the training set and one-third is used in the testing 
set. The accuracy of the classifier is the sum of the sensitivity and specificity of the testing set. 
For the DT algorithm, all samples are used in the construction of the decision tree. After the 
best decision tree is constructed from the evolutionary programming search over ordered 
sets of seven features, one-third of the samples are removed to build the testing set. This is 
done in a way that does not change the description of each terminal node (i.e. it stays as 
either a healthy or diseased node) and the sensitivity and specificity of the training and 
testing sets are approximately equal. This may appear to be cheating, but the goal of this 
investigation is to determine the minimum accuracy that could be obtained from data that 
contains no information. 
The best quality from the five datasets for each number of Cases and Controls is given in 
Table 1. For 30 Cases and 30 Controls, a 7-node decision tree was able to correctly 
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classify all 60 samples. In other words, all eight terminal nodes only contained samples 
from a single group. For 60 Cases and 60 Controls, a decision tree correctly classifies over 
89% of the testing samples, and for 90 Cases and Controls, over 83% of the testing 
samples were correctly classified. It is only when the number of samples is as large or 
larger than the number of features that the DT classifier drops below 80% accuracy for 
the testing data. 
Cases and 
Controls 
DT MCA
5-Feat 6-Feat 7-Feat 
30 200.0 200.0 200.0 200.0 
42 190.5 197.6 197.6 197.6 
60 178.3 193.3 193.3 195.0 
90 166.7 187.8 188.9 191.1 
150 155.3 183.3 185.3 187.3 
300 138.3 170.3 179.0 180.3 
Table 1. Highest quality obtained using absolute differences in un-scaled peak intensities, 
from a decision tree (EPDT) and the medoid classifier algorithm (MCA). Note: Taken from 
[Luke & Collins, 2008] where the quality is the sum of the sensitivity and specificity. 
The classifier constructed by the MCA is order dependent in that the first training sample 
automatically becomes the medoid of the first region. Therefore, this analysis uses all 
samples to construct a classifier with the requirement that the samples used as medoids 
cannot exceed two-thirds of either the Cases or Controls. One-third of the samples from each 
group are then selected as testing samples and are chosen such that the accuracy of the 
training set is at least as high as the testing set. 
The results in Table 1 show that an MCA classifier performs excellently using datasets that 
contain no information. If only seven of the 300 features are used, one can find a classifier 
with an average sensitivity and specificity of over 90% even when there are 300 Cases and 
300 Controls (200 of each in the training set and 100 of each in the testing set). If the number 
of features is reduced to five or six, the accuracy stays above 90% for all but the largest 
datasets. 
3.2 SVM and LDA classifiers 
The results for the SVM and LDA classifiers are shown in Table 2. As described above, all 
samples are used to determine which features will be used in the classifier, but the accuracy 
of the final classification uses the sum of the sensitivity and specificity of the testing set for 
10-fold cross-validation, averaged over 100 runs where the order of the samples are 
scrambled before each run. SVM has an average classification accuracy over 97% when there 
are 90 or fewer Cases and Controls in the dataset. For LDA, the average accuracy stays 
above 99.7%. 
For the larger datasets, the accuracy decreases significantly. When there are 150 Cases and 
150 Controls, the SVM and LDA classifiers have an average accuracy of about 87 and 84%, 
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respectively. This is better than a 7-node decision tree, but not as good as any of the MCA 
classifiers examined. Datasets that contain 300 Cases, 300 Controls, and only 300 features 
have SVM and LDA accuracies of 61.3 and 63.7% respectively, which is below the accuracy 
of the DT and MCA classifiers. 
Cases and Controls 
 
SVM 
 
LDA 
30 198.50 199.06 
42 199.88 199.84 
60 199.02 199.68 
90 194.82 199.52 
150 174.38 167.90 
300 132.66 135.44 
Table 2. Highest quality obtained using normalized feature values from support vector 
machine (SVM) and linear discriminate analysis (LDA) classifiers. Note: The quality is the 
sum of the sensitivity and specificity for the testing set averaged over 100 runs of 10-fold 
cross-validation. 
3.3 BMDK Classifier 
The accuracy of the BMDK classifier is shown in Table 3. This accuracy is determined from a 
leave-one-out cross-validation, a procedure that is known to exaggerate the accuracy of a 
classifier. After each sample is classified, the overall accuracy is the sum of the sensitivity and 
specificity minus the percentage of samples that were classified as unknown. For the smallest 
dataset (30 Cases and 30 Controls) a 3-feature DD-KNN classifier correctly classified 78.9% of 
the samples. In general, the accuracy decreased as the number of samples increased. 
Cases and Controls 
 
BMDK 
1-Feat 2-Feat 3-Feat 
30 147.4 153.3 157.8 
42 142.9 136.4 137.3 
60 151.7 140.0 140.1 
90 123.3 137.9 137.3 
150 118.0 127.3 125.3 
300 115.7 121.7 122.1 
Table 3. Highest quality obtained from the BioMarker Development Kit (BMDK) using 
absolute differences in un-scaled peak intensities. Note: The quality is the sum of the 
sensitivity and specificity minus the percent of samples undetermined using a leave-one-out 
cross-validation of the entire set of data. 
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The only exception was for one dataset with 60 Cases and 60 Controls. This increased 
accuracy was due to an unusual pattern in one of the randomly generated features. The 
intensities for this feature are shown in Figure 5, where the “+” marks in the left column are 
the intensities of the 60 samples in Group-1 and the marks in the right column are for the 60 
samples in Group-2. While there is no overall difference between these columns, a closer 
examination shown a clumping of intensities in one group at values that have gaps in the 
other group. 
 
 
 
 
Fig. 5. Intensities for the 60 cases (left column) and 60 controls (right column) for the peak 
that yielded a quality score of 151.7 (sensitivity=78.3%, specificity=73.3%, 
undetermined=0.0%) in the dataset of random peak intensities. 
In many cases the accuracy of a 3-feature classifier is not significantly better than a 2-feature 
classifier. This is due to the fact that as the dimensionality of the classification space 
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increases, the separation between the samples becomes larger. This causes more samples to 
be classified as Undetermined. For this reason, no 4-feature classifier did better than the 
3-feature classifier in any of the 30 datasets. 
4. Discussion 
The results presented in the tables above show that very good results can be obtained from 
DT, MCA, SVM and LDA classifiers for datasets that contain no information. It can be 
argued that the procedures used here are selected to obtain the maximum possible accuracy, 
and that is exactly the point. If a 7-node decision tree used 40 Cases and 40 Controls in the 
training set and 20 Cases and 20 Controls in the testing set and obtained an accuracy of 
87.5% for the testing samples, one could propose that the set of seven features denotes a 
fingerprint that accurately classifies the samples. The results in Table 1 show that this 
accuracy can be obtained from a dataset with only 300 randomly generated feature values 
for each sample. A 7-feature MCA classifier is able to achieve an average accuracy of over 
90% when the dataset contains 300 Cases, 300 Controls, and only 300 non-informative 
features. This should draw into question the results of any study that uses this classification 
method. 
SVM and LDA classifiers have testing set accuracies above 97.4 and 99.7%, respectively, for 
all but the largest datasets. It is only when the number of samples is at least as large as the 
number of features that these methods break down. Current methods for obtaining 
information from biological samples generate many more features that the 300 used here. 
The BMDK classifier did not achieve an average accuracy above 80% for even the smallest 
dataset. This result is not unexpected. Since the datasets do not contain any information, 
there are no biomarkers and a biomarker-based classifier should not perform well. 
Fortuitous results can be obtained and a closer examination of the putative biomarkers 
should be performed (Figure 5). 
For the DT and MCA methods there is some selection of which samples should be placed 
in the training and testing sets, but this is basically what is required because of the 
coverage problem. If a given terminal node in a DT classifier contains 7 Cases and 4 
Controls, and 4 of the Cases were moved to the testing set, this terminal node would 
change from a Case-node to a Control-node and the classification accuracy of the testing 
data would be decreased. The MCA classifier is based on the premise of a fingerprint that 
associates a sample in the testing set with a sample in the training set. If that sample were 
removed from the training set, the association could not be made and the accuracy of the 
classifier would be decreased. 
5. Conclusions 
The results presented here show that very good classification results can be obtained from 
DT, MCA, SVM, and LDA classifiers, even if the dataset contains no information. Studies 
using any of these methods should carefully examine whether the results are due to some 
underlying biology or are just fortuitous. Performing comparable examinations on 
randomly generated feature values, or performing analysis of the same data after the 
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group labels of the samples has been scrambled, should be a necessary part of these 
investigations. 
In contract, a biomarker-based classifier such as BMDK should perform poorly if the dataset 
contains no biological information. Even when reasonably good results are obtained, the 
putative biomarkers used in the classifier should be carefully examined to ensure that they 
really distinguish samples in one group from the other. 
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